REG-Bioventix Plc: Director/PDMR Shareholding <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

20/10/2015 16:00

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                               Director dealing                                

Bioventix plc (AIM: BVXP) was notified today that on 19 October 2015, Ian
Nicholson, Chairman of the Company, and connected persons, sold 5,000 ordinary
shares of 5 pence each ("Ordinary Shares") at a price of 1,115 pence per
Ordinary Share (the "Sale"). Following the Sale, Mr Nicholson holds 27,000
Ordinary Shares (13,000 of which are held in the name of his wife),
representing approximately 0.5% of the issued share capital of the Company.

For further information please contact:

Bioventix plc                                             Tel: 01252 728 001         
Peter Harrison               Chief Executive Officer                                 
                                                                                     
finnCap Ltd                                               Tel: 020 7220 0500         
Geoff Nash/Simon Hicks       Corporate Finance                                       
Steve Norcross               Corporate Broking                                       

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



END



Copyright © 2015 PR Newswire Association, LLC. All Rights Reserved